Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor
Open accessThe DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index; 25 of the 72 sources its claims cite were checked for support.
Abstract
Cellular senescence suppresses cancer by arresting cell proliferation, essentially permanently, in response to oncogenic stimuli, including genotoxic stress. We modified the use of antibody arrays to provide a quantitative assessment of factors secreted by senescent cells. We show that human cells induced to senesce by genotoxic stress secrete myriad factors associated with inflammation and malignancy. This senescence-associated secretory phenotype (SASP) developed slowly over several days and only after DNA damage of sufficient magnitude to induce senescence. Remarkably similar SASPs developed in normal fibroblasts, normal epithelial cells, and epithelial tumor cells after genotoxic stress in culture, and in epithelial tumor cells in vivo after treatment of prostate cancer patients with DNA-damaging chemotherapy. In cultured premalignant epithelial cells, SASPs induced an epithelial-mesenchyme transition and invasiveness, hallmarks of malignancy, by a paracrine mechanism that depended largely on the SASP factors interleukin (IL)-6 and IL-8. Strikingly, two manipulations markedly amplified, and accelerated development of, the SASPs: oncogenic RAS expression, which causes genotoxic stress and senescence in normal cells, and functional loss of the p53 tumor suppressor protein. Both loss of p53 and gain of oncogenic RAS also exacerbated the promalignant paracrine activities of the SASPs. Our findings define a central feature of genotoxic stress-induced senescence. Moreover, they suggest a cell-nonautonomous mechanism by which p53 can restrain, and oncogenic RAS can promote, the development of age-related cancer by altering the tissue microenvironment.
Overview
CoChat Summary
TL;DR
Senescent human fibroblasts and epithelial cells develop a complex senescence-associated secretory phenotype (SASP) that can promote malignant phenotypes in neighboring cells, including epithelial–mesenchymal transition (EMT) and invasion. Oncogenic RAS and loss of p53 amplify and accelerate this SASP, suggesting p53 acts as a cell-nonautonomous tumor suppressor by restraining protumorigenic secreted factors.
Key findings
- Of 120 proteins assayed, 41 were significantly oversecreted by senescent cells compared with presenescent cells, while 79 showed no significant difference; the SASP included inflammatory cytokines/chemokines, growth factors, shed surface molecules, and survival factors.
- The SASP was conserved across cell types: normal fibroblasts and normal prostate epithelial cells overlapped significantly (p ≈ 10⁻³; r = 0.53; >66% overlap), and 24 proteins were shared between all fibroblast and all epithelial SASPs (p ≈ 10⁻⁵).
- SASP induction required genotoxic stress sufficient to cause senescence: 10 Gy X-irradiation induced a SASP, whereas 0.5 Gy did not; the SASP developed slowly, requiring 4–7 d after irradiation.
- Oncogenic RAS induced an amplified SASP: correlations with REP/XRA SASPs were 0.75 for WI-38/IMR-90 and 0.84 for HCA-2 fibroblasts; nine proteins were significantly more secreted in SEN(RAS) versus SEN(REP;XRA) across all fibroblasts, plus five RAS-unique proteins.
- p53 loss was not required to initiate or maintain a SASP, but it amplified it: a subset of SASP proteins was secreted at 5- to 30-fold higher levels after p53 inactivation, and combined p53 loss plus oncogenic RAS produced the most amplified SASP, with accelerated development within 2–4 d.
- SASP factors induced EMT and invasion in nonaggressive breast cancer cells; IL-6 and IL-8 blocking antibodies reduced SEN CM–stimulated invasion.
- In human prostate cancer biopsies after mitoxantrone chemotherapy, tumors showed higher p16INK4a and p21 mRNAs, lower cyclin A, MCM-3, and PCNA mRNAs, and higher mRNAs for IL-6, IL-8, GM-CSF, GRO-α, IGFBP-2, and IL-1β, while IL-2 mRNA did not significantly change.
Methods
- Human fibroblast strains (WI-38, IMR-90, BJ, HCA2, hBF184), normal prostate epithelial cells (PrECs), and prostate tumor lines (BPH1, RWPE1, PC3) were induced to senesce by replicative exhaustion (REP), 10 Gy X-irradiation (XRA), oncogenic RAS, or mitoxantrone (MIT); p53 was inactivated using GSE22 or shRNA.
- Conditioned media were analyzed with modified antibody arrays detecting 120 proteins, using ³⁵S-streptavidin detection for improved dynamic range; findings were validated by ELISA, immunostaining, invasion assays, and RT-PCR.
- Human prostate cancer biopsies were obtained before and after MIT chemotherapy; approximately 1,000 tumor epithelial cells were laser-captured per sample, and mRNA was quantified by RT-PCR. Statistical analyses used Pearson correlation, two-tailed Student t-test, and hypergeometric distribution for SASP overlap.
Limitations
- The paper does not include a formal limitations section.
- Evident from the text: the in vivo human SASP evidence relies on mRNA from laser-captured tumor cells rather than direct measurement of secreted proteins, with approximately 1,000 cells captured per sample.
- Evident from the text: many mechanistic conclusions come from cultured cells, and the SASP is described as not a fixed phenotype, with quantitative and qualitative differences among cell strains, tissues, and donors.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Chemotherapy-Induced SASP in Culture and In Vivo (A) Overall correlation between XRA and mitoxantrone (MIT)-induced SASPs for all three prostate epithelial cancer cell lines (BPH-1, RWPE-1, and PC-3). Correlations for the individual cell lines are given in the table to the right. The senescence inducer (XRA or MIT) is given in parentheses. (B–E) Human tumor cells were isolated from biopsies obtained from the same patient before MIT chemotherapy and from prostate tissue following prostatectomy after MIT chemotherapy. Laser captured cells were analyzed by quantitative RT-PCR for the mRNAs encoding the indicated proteins, as described in Materials and Methods and Text S1. The results are displayed on a log10 scale indicating the values before (horizontal or x-axis) compared to after (vertical or y-axis) chemotherapy (top left panel in [B]). Each black dot in (B, C, and D) represents the results obtained from a single patient. The average values for all patients before versus after chemotherapy are indicated by a red dot (B–D); these values are also represented as a heat map in (E). (B) Values for mRNAs encoding proteins associated with senescence (p16 and p21) and proliferation (cyclin A, MCM-3, and PCNA). (C) Values for mRNAs encoding SASP-associated proteins (IL-6, IL-8, GM-CSF, GRO-α, IGFBP-2, and IL-1β). (D) Value for an mRNA encoding a non-SASP–associated protein (IL-2). (E) Averages for the values shown in (B–D). Overall p-values, determined by the Student t-test, and number of paired samples (or patients) analyzed for each mRNA are given to the right of the heat map. Signals higher than the prechemotherapy baseline are shown in red; signals below baseline are displayed in green.](https://figures.cochat.ai/paper-figures/92013b1ef9b3492d8c26b76b40577c28/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-3.jpg)


![Figure 6 p53 Restrains the SASP (A) CM containing factors secreted by the indicted cells were analyzed by antibody arrays and displayed, using PRE CM as the baseline. We pooled data from cells of the same genotype (p53 wild type or p53 deficient) under the same culture conditions. SEN indicates pooled data from cells originating from the same tissue (WI-38, IMR-90 from embryonic lung; and HCA-2, BJ from neonatal foreskin) and induced to senesce by REP or XRA. Pooling and averaging of highly correlated samples was performed as described for Figure 5, and details of the data processing are provided in Datasets S13–S16. The top four rows are the same top four rows in Figure 5A and are included to serve as a visual reference. The senescence inducer is given in parentheses. p53 status is indicated as either wild type (wt) or deficient (d) owing to either GSE22 expression or expression of an shRNA against p53. Manipulations are indicated in sequence, separated by a greater than symbol (>). The heat map key (right) indicates the log2-fold changes. Signals higher than the baseline are shown in yellow; signals below baseline are displayed in blue. Comparison between rows is accurately illustrated in (B) and (C) in which each genetically manipulated cell type is compared to its appropriate control baseline. (B) Log2-fold values for SASP factors that are significantly increased, or significantly and uniquely (as indicated by double asterisks [**]) elevated, in CM from SEN cells made p53 deficient by GSE22, using untreated wild-type SEN values as the baseline. Green indicates WI-38 cells made senescent by XRA, after which p53 was subsequently inactivated by expressing GSE22 using a lentivirus; these cells do not resume proliferation (“unreverted”) upon p53 inactivation (see Figure S6). Blue indicates WI-38 in which p16 was inactivated by an shRNA, induced to senesce by XRA, then infected with the GSE22-expressing lentivirus; these cells do revert (REV) after p53 inactivation. Pink indicates HCA2 cells made SEN by XRA, then infected with GSE22 lentivirus; these cells also revert after p53 inactivation. (C) Log2-fold values for SASP factors that are significantly increased, or significantly and uniquely (as indicated by double asterisks [**]) elevated, in CM from cells made p53-deficient (by GSE22 expression), then induced to senesce by REP, XRA, or RAS. Red indicates WI-38 and IMR90 (averaged) cells expressing GSE22, then induced to senesce by XRA or REP, using cells made SEN by XRA or REP as a baseline. Gray indicates WI-38, IMR-90, and HCA2 (averaged) expressing GSE22, then made senescent by RAS, using SEN by RAS as a baseline. (D) WI-38 cells expressing GSE22 were induced to senesce by XRA and then immunostained for the SASP proteins IL-6 and IL-8, the senescence marker p16INK4a, and p53, which accumulates in the presence of GSE22. (E) Comparative graphical representation of the secretory profiles of cells made senescent by XRA or REP (dotted line), RAS (black line), p53 inactivation (GSE22) followed by XRA or REP (blue line), or p53 inactivation (GSE22) followed by RAS (red line). The increased slopes (as indicated by the arrow)indicate amplified SASPs. (F) Hierarchical cluster analysis of all the cells analyzed in (A), plus the SASP induced by RAS (see Figure 5). RAS status is indicated as either wild type (wt) or oncogenic (o) owing to expression of Ha-RASv12. (G) WI-38 cells with wild-type (wt) or inactive (GSE) p53 were irradiated or induced to express oncogenic RAS (RAS), and CM was collected 4 or 10 d later. Soluble factors were analyzed by antibody arrays and displayed as described in Figure 1D, using PRE CM as the baseline (black column on the left; see also Figure S5C for details). Signals higher than baseline are shown in yellow; signals below baseline are in blue. n/a, not applicable. (H) Log2-fold values for prostate epithelial cell SASP factors that are significantly or uniquely (as indicated by double asterisks [**]) elevated in CM from p53-deficient cancer cells (PC3, BPH1, and RWPE1) that were induced to senesce by XRA, compared to primary p53 wild-type cells (PrECs) that were induced to senesce by XRA.](https://figures.cochat.ai/paper-figures/ec6066e9173e4732bc7f9d2c5718a2dd/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-6.jpg)
![Figure 7 Biological Activities of the Amplified SASP (A) T47D and ZR75.1 cells were incubated with the indicated CM for 3 d and then analyzed for cell scattering, immunostained for the indicated proteins, and analyzed for vimentin and actin levels by western blotting. Controls for the immunofluorescence from the same individual experiment are shown in Figure 4B. The senescence inducer is given in parentheses. p53 status was either wild type or deficient (GSE). Manipulations are indicated in sequence, separated by >. (B) Epithelial cells were incubated with CM from the indicated WI-38 cells and assayed for invasion as described in Materials and Methods and Figure 3C. Double asterisks (**) indicate p < 0.02. Error bars indicate the standard deviation around the mean. (C) Epithelial cells were incubated with CM from the indicated fibroblasts and cell number was determined by cell counting, total protein, or green fluorescent protein (GFP) fluorescence using epithelial cells expressing GFP, as described in [80]. A single asterisks (*) indicates p < 0.05. Error bars indicate the standard deviation around the mean. (D) Model for the cell-nonautonomous activities of oncogenic RAS and the p53 tumor suppressor protein. Oncogenic and genotoxic stress of sufficient magnitude to cause senescence induce a SASP, whereby cells secrete inflammatory cytokines, chemokines, and growth factors that can alter the tissue microenvironment and stimulate malignant phenotypes in nearby cells. Thus, in addition to their well-known cell-autonomous effects, oncogenes can promote cancer cell-nonautonomously by inducing a SASP. Oncogenic and genotoxic stress also activate p53, which suppresses cancer by cell-autonomous mechanisms (promoting repair, or inducing apoptosis or senescence). In addition, p53 suppresses cancer by the cell-nonautonomous effects of suppressing the intensity of the SASP and its deleterious effects.](https://figures.cochat.ai/paper-figures/c8eed762510f438c8789f2db0ec751a6/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-7.jpg)
Verification
Claims the paper makes
19 Valid · 4 Not valid · 9 Not checked · 117 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lastly, in mice and humans, a senescence response to strong mitogenic signals, such as those delivered by certain oncogenes, prevents premalignant lesions from progressing to malignant cancers [ 16 – 19 ].”
What the sources say
- Not checked — no full text of the sourcecites [16] Collado, 2005, Nature source
- Partly supportedcites [17] Chen, 2005, Nature sourceExperimental — accuracy not yet measured
The Abstract reports that p53-dependent senescence restricts Pten-deficient tumorigenesis in mice, and the human-specimen passage reports senescence staining mainly in prostate hyperplasia or PIN rather than frank tumour (page numbers unavailable). The human observations do not establish that senescence prevents progression, and the experimental finding concerns Pten loss rather than strong mitogenic signals generally. (LLM, conf=0.86)
- Partly supportedcites [18] Michaloglou, 2005, Nature sourceExperimental — accuracy not yet measured
The discussion (Nature, vol. 436, 4 August 2005; page not provided) says the findings support oncogene-induced senescence as a mechanism in humans that limits progression of premalignant lesions. The paper studies human melanocytes and naevi, not mice, and describes limitation of progression rather than categorical prevention. (LLM, conf=0.88)
- Not matchedcites [19] Braig, 2005, Nature
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Consistent with this view, senescent cells increase with age in mammalian tissues [ 27 ]”
What the sources say
- Supportedcites [27] Campisi, 2005, Cell source
The “Cellular Senescence and Aging” passage (page not provided) says that cells with characteristics of senescence accumulate with age in multiple tissues from humans and rodents. This supports the claim about mammalian tissues. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Senescent cells acquire many changes in gene expression, mostly documented as altered mRNA abundance, including increased expression of secreted proteins [ 33 – 41 ].”
What the sources say
- Partly supportedcites [33] Zhang, 2003, Proc Natl Acad Sci U S A sourceExperimental — accuracy not yet measured
The Results report hundreds of changes in transcript abundance during senescence in human fibroblasts, supporting the claim about altered gene expression measured as mRNA. They identify up-regulated genes encoding membrane-associated proteins, but the passages in our copy do not establish increased expression of secreted proteins; membrane-associated is not the same as secreted. (LLM, conf=0.85)
- Supportedcites [34] Chang, 2002, Proc Natl Acad Sci U S A source
The Results and Discussion report many gene-expression changes in senescent HCT116 cells, measured primarily with RNA-based methods, and specifically identify increased expression of genes for secreted factors. The paper also notes parallels with senescence in normal cells. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [35] Bavik, 2006, Cancer Res source
- Not checked — no full text of the sourcecites [36] Mason, 2004, Oncogene source
- Not checked — no full text of the sourcecites [37] Wajapeyee, 2008, Cell source
- Not matchedcites [38] Kortlever, 2006, Nat Cell Biol
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not checked — no full text of the sourcecites [39] Parrinello, 2005, J Cell Sci source
- Supportedcites [40] Kuilman, 2008, Cell source
The Results (page not provided) report genome-wide expression analysis showing multiple gene classes upregulated during oncogene-induced senescence, including cytokine and chemokine genes. They also report increased IL-6 and IL-8 expression and secretion of IL-6 by senescent cells, supporting the claim about secreted proteins. (LLM, conf=0.91)
- Supportedcites [41] Acosta, 2008, Cell source
The Discussion (page unavailable) identifies increased production of various secreted proteins as a characteristic of senescent cells. It also reports that CXCR2 and many of its ligands are upregulated during senescence, supporting the claim about changes in expression. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Thus, oncogenes such as RAS, which are known to activate protumorigenic paracrine mechanisms during transformation [ 59 – 61 ], might also exert cell-nonautonomous protumorigenic effects through nontransformed cells during the process of inducing senescence ( Figure 7 D).”
What the sources say
- Supportedcites [59] Ancrile, 2007, Genes Dev source
The citation supports the sentence’s background clause about protumorigenic paracrine mechanisms during RAS-driven transformation. The Abstract says RAS-induced IL6 acts in a paracrine fashion to promote angiogenesis and tumor growth; the Summary likewise describes this effect in RAS-driven tumor cells. The later suggestion about senescence is the citing authors’ own inference, not a finding attributed to this source. (LLM, conf=0.92)
- Supportedcites [60] Yang, 2006, Proc Natl Acad Sci U S A source
The Discussion states that RAS signals to stromal cells through Gro-1, inducing senescence and promoting tumor growth or malignant transformation. The paper’s opening summary also reports that Gro-1-induced senescent fibroblasts promote tumor growth, supporting the proposed cell-nonautonomous effect. Page numbers are not provided in our copy. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [61] Akhurst, 2001, Trends Cell Biol source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Our results showed that human tumor cells very likely undergo senescence in response to DNA damaging chemotherapy in vivo, as reported for mice [ 49 ].”
What the sources say
- Supportedcites [49] Schmitt, 2002, Cell source
The citation is attached to “as reported for mice,” not to the citing authors’ finding about human tumor cells. The cited paper’s Discussion reports chemotherapy-induced senescence in vivo in a murine lymphoma model; it does not itself establish the human finding. (LLM, conf=0.93)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
89 more claims · 3 with their cited sources checked
Create a free account to see all 149 claims and every source verdict.
- Probably not a substantial claim. 18
- It may state two separate claims as one. 41
- Borderline: one of the tests for a substantial claim is unclear. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“the effects of the senescent fibroblasts were due primarily to their secretion of matrix metalloproteinases (MMPs), which are prominent SASP components (32, 94).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Senescent cells are metabolically active and can acquire a pro-inflammatory, tissue-destructive, pro-apoptotic senescence-associated secretory phenotype (SASP) [26]”
From Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease (2019) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“although it was robustly induced 7–10 days after cultured MEFs were stimulated to senesce by IR (Coppé et al., 2008)”
From An Essential Role for Senescent Cells in Optimal Wound Healing through Secretion of PDGF-AA (2014) · cites this paper as Coppé et al., 2008
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SASP is primarily a property of cells that senesce owing to, or accompanied by, genomic damage or epigenomic perturbation.”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many types of cytotoxic chemotherapies are severe DNA-damaging agents that can induce senescence in both tumor cells and surrounding normal cells (31–34).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Experimental — accuracy not yet measured
80 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9363 · Cited by 7,477
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 5×
“We thank R. Driver for support with the array experiments, J. Gray and R. Neve for discussions, cells, and use of Cellomix; A. Huang for help with the microdissection and PCR; A. Zielinski and J. Allison for technical help; T. Beer, M. Garzotto, C. Higano, L. True, R. Vessella, and the University of Washington Medical…”
BackgroundMethodInfluentialOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“prototype [56], induce senescence in part by indirectly”
BackgroundCellular senescence: when bad things happen to good cells
Campisi, J., & d'Adda di Fagagna, F. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2233 · Cited by 4,441 · cited 1×
“Several lines of evidence indicate that cellular senescence is a potent tumor-suppressive mechanism [4,9,10].”
BackgroundSelf-citationPleiotropy, natural selection, and the evolution of senescence.
Williams, G. C. (1957) · Evolution · doi:10.1111/j.1558-5646.1957.tb02911.x · Cited by 4,279 · cited 1×
“It is now recognized that aging is a consequence of the declining force of natural selection with age [26,70].”
BackgroundDNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · cited 1×
“Moreover, human cells that bypass oncogene-induced senescence [58], as well as cells in some human premalignant lesions [73,74], show signs of a persistently activated DDR.”
BackgroundSenescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · cited 1×
“Recent findings show that tumors induced to senesce in mice gradually regress [21,22], owing perhaps to infiltration by cells of the innate immune system [22].”
BackgroundSenescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors
Campisi, J. (2005) · Cell · doi:10.1016/j.cell.2005.02.003 · Cited by 2,379
Research works printed but not linked: 80
- Hanahan, 2000, Cell, 100, 57
- Bissell, 2001, Nature Rev Cancer, 1, 46
- Coussens, 2002, Nature, 420, 860
- Campisi, 2007, Nature Rev Molec Cell Biol, 8, 729
- Dimri, 2005, Cancer Cell, 7, 505
- Ben-Porath, 2004, J Clin Invest, 113, 8
- Chau, 2003, Nature Rev Cancer, 3, 130
- Bargonetti, 2002, Curr Opin Oncol, 14, 86
- Braig, 2006, Cancer Res, 66, 2881
- Campisi, 2003, Nature Rev Canc, 3, 339
- Wright, 2001, Curr Opin Genet Dev, 11, 98
- Collins, 2003, Aging Cell, 2, 145
- Lowe, 2003, Curr Opin Genet Dev, 13, 77
- Ohtani, 2004, J Med Invest, 51, 146
- Gil, 2006, Nature Rev Molec Cell Biol, 7, 667
- Collado, 2005, Nature, 436, 642
- Chen, 2005, Nature, 436, 725
- Michaloglou, 2005, Nature, 436, 720
- Braig, 2005, Nature, 436, 660
- Shay, 2004, Oncogene, 23, 2919
- Ventura, 2007, Nature, 445, 661
- Xue, 2007, Nature, 445, 656
- Donehower, 2002, J Cell Physiol, 192, 23
- Faragher, 2000, Biochem Soc Trans, 28, 221
- Kortlever, 2006, Cell Cycle, 5, 2697
- Kirkwood, 2000, Nature, 408, 233
- Campisi, 2005, Cell, 120, 1
- Price, 2002, Aging Cell, 1, 57
- Vasile, 2001, FASEB J, 15, 458
- Matthews, 2006, Circ Res, 99, 156
- Maier, 2004, Genes Dev, 18, 306
- Tyner, 2002, Nature, 415, 45
- Zhang, 2003, Proc Natl Acad Sci U S A, 100, 3251
- Chang, 2002, Proc Natl Acad Sci U S A, 99, 389
- Bavik, 2006, Cancer Res, 66, 794
- Mason, 2004, Oncogene, 23, 9238
- Wajapeyee, 2008, Cell, 132, 363
- Kortlever, 2006, Nat Cell Biol, 8, 877
- Parrinello, 2005, J Cell Sci, 118, 485
- Kuilman, 2008, Cell, 133, 1019
- Acosta, 2008, Cell, 133, 1006
- Krtolica, 2001, Proc Natl Acad Sci U S A, 98, 12072
- Liu, 2007, Cancer Res, 67, 3117
- Parrinello, 2003, Nat Cell Biol, 5, 741
- Hayward, 1995, In Vitro Cell Dev Biol Anim, 31, 14
- Bello, 1997, Carcinogenesis, 18, 1215
- Kaighn, 1979, Invest Urol, 17, 16
- Chang, 1999, Oncogene, 18, 4808
- Schmitt, 2002, Cell, 109, 335
- Tannock, 2004, N Engl J Med, 351, 1502
- Cowin, 2005, Curr Opin Cell Biol, 17, 499
- Kokkinos, 2007, Cells Tissues Organs, 185, 191
- Dhawan, 2005, J Clin Invest, 115, 1765
- Yuan, 2005, Front Biosci, 10, 853
- Badache, 2001, Cancer Res, 61, 383
- Serrano, 1997, Cell, 88, 593
- Di Micco, 2006, Nature, 444, 638
- Mallette, 2007, Genes Dev, 21, 43
- Ancrile, 2007, Genes Dev, 21, 1714
- Yang, 2006, Proc Natl Acad Sci U S A, 103, 16472
- Akhurst, 2001, Trends Cell Biol, 11, 44
- Beausejour, 2003, EMBO J, 22, 4212
- Ossovskaya, 1996, Proc Natl Acad Sci U S A, 93, 10309
- Mantovani, 2006, Nature Rev Immunol, 6, 907
- Jeyapalan, 2007, Mech Ageing Dev, 128, 36
- Dimri, 1995, Proc Natl Acad Sci U S A, 92, 9363
- Paradis, 2001, Hum Pathol, 32, 327
- Melk, 2003, Kidney Int, 63, 2134
- Bruunsgaard, 2001, Curr Opin Hematol, 8, 131
- Williams, 1957, Evolution, 11, 398
- Roberts, 2006, Eur Spine J, 15, 312
- Herbig, 2006, Science, 311, 1257
- Bartkova, 2005, Nature, 434, 864
- Gorgoulis, 2005, Nature, 434, 907
- Kiaris, 2005, Cancer Res, 65, 1627
- Hill, 2005, Cell, 123, 1001
- Coppe, 2006, J Biol Chem, 281, 29568
- Kaminker, 2005, J Cell Sci, 118, 1321
- Kim, 2004, J Biol Chem, 279, 43799
- Krtolica, 2002, Cytometry, 49, 73
Cited by
Items 701–800 of 4,275
Morgan, R. G., Ives, S. J., Lesniewski, L. A., Cawthon, R. M., Andtbacka, R. H. I., Noyes, R. D., Richardson, R. S., & Donato, A. J. (2013) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00197.2013 · Cited by 115
“Secondary outcomes included P21, IL6, IL8, and MCP1 mRNA expression.”
BackgroundInfluentialDDR-mediated crosstalk between DNA-damaged cells and their microenvironment
Malaquin, N., Carrier-Leclerc, A., Dessureault, M., & Rodier, F. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00094 · Cited by 113
“…senescent cells from most species and tissues that are triggered by various stresses all display a Senescence-Associated Secretory Phenotype (SASP; Figure 1B), which is critical for the ability of these cells to modulate their microenvironment (Coppe et al., 2008, 2010a,b; Ohanna et al., 2011).”
BackgroundSelf-citationBouvier, D., Forest, J., Blanchon, L., Bujold, E., Pereira, B., Bernard, N., Gallot, D., Sapin, V., & Giguère, Y. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8111987 · Cited by 153
“Recent reports indicated that PPROM might be associated with the presence of sterile inflammation in the fetal membranes [27,28].”
BackgroundPolyphenols as Caloric-Restriction Mimetics and Autophagy Inducers in Aging Research
Yessenkyzy, A., Saliev, T. M., Zhanaliyeva, M., Masoud, A., Umbayev, B. A., Sergazy, S., Кривых, Е. А., Gulyayev, A., & Nurgozhin, T. S. (2020) · Nutrients · doi:10.3390/nu12051344 · Cited by 121
Xu, P., Wang, M., Song, W.-M., Wang, Q., Yuan, G.-C., Sudmant, P. H., Zare, H., Tu, Z., Orr, M. E., & Zhang, B. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00507-7 · Cited by 114
“In contrast, only 10% of the total SASP factors (n = 3,513) in the human genome were upregulated, suggesting the aggregated network was significantly enriched for the SASP factors in senescent cells (FET p = 1.9e-15).”
BackgroundInfluentialCellular senescence: Its role in tumor suppression and aging
Ohtani, N., Mann, D. J., & Hara, E. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01123.x · Cited by 114
Byun, H.-O., Lee, Y.-K., Kim, J.-M., & Yoon, G. (2015) · BMB Reports · doi:10.5483/bmbrep.2015.48.10.122 · Cited by 115
“fibronectin (51), PAI (52), and several SASP components (53, 54).”
BackgroundThe Paradoxical Role of Cellular Senescence in Cancer
Yang, J., Liu, M., Hong, D., Zeng, M., & Zhang, X. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.722205 · Cited by 114
“In vitro dormancy model of MCF-7 breast cancer cells, bone marrow stroma secretory senescence (IL-6, IL-8, and TGFβ1) could reactivate dormant MCF-7 cells by promoting their phenotype to mesenchymal appearance, resulting in cellular proliferation and migration (Sun et al., 2018).”
BackgroundResultInfluentialDi, G.-H., Liu, Y., Lu, Y., Liu, J., Wu, C., & Duan, H.-F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113572 · Cited by 114
“The altered expression of inflammatory factors, growth cytokines and matrix metalloproteinases could disrupt tissue architecture and function, and then, create a microenvironment that facilitates the growth and progression of the mutant epithelial cells [33].”
BackgroundColucci, M., Sarill, M., Maddalena, M., Valdata, A., Troiani, M., Massarotti, M., Bolis, M., Bressan, S., Kohl, A., Robesti, D., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.05.015 · Cited by 164
Role of Oxidative Stress in Ocular Diseases: A Balancing Act
Shu, D. Y., Chaudhary, S., Cho, K., Lennikov, A., Miller, W. P., Thorn, D. C., Yang, M., & McKay, T. B. (2023) · Metabolites · doi:10.3390/metabo13020187 · Cited by 131
Systemic induction of senescence in young mice after single heterochronic blood exchange
Jeon, O. H., Mehdipour, M., Gil, T.-H., Kang, M., Aguirre, N. W., Robinson, Z. R., Kato, C., Etienne, J., Lee, H. G., Alimirah, F., et al. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00609-6 · Cited by 114
“1c,d), (3) reduced cell proliferation, as measured by 5-ethynyl-2′-deoxyuridine (EdU) incorporation (Fig.”
BackgroundPharmacological CDK4/6 inhibition reveals a p53‐dependent senescent state with restricted toxicity
Wang, B., Varela‐Eirin, M., Brandenburg, S. M., Hernandez‐Segura, A., van Vliet, T., Jongbloed, E. M., Wilting, S. M., Ohtani, N., Jager, A., & Demaria, M. (2022) · The EMBO Journal · doi:10.15252/embj.2021108946 · Cited by 113
Igarashi, K., & Watanabe‐Matsui, M. (2014) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.232.229 · Cited by 128
“SASP is a phenotype in which senescent human fibroblastic cells secrete a diverse array of cytokines and chemokines, including Il-6, -7, MCP-2, GRO and HGF (Coppe et al. 2008).”
Hit-and-run epigenetic editing prevents senescence entry in primary breast cells from healthy donors
Saunderson, E. A., Stepper, P., Gomm, J. J., Hoa, L., Morgan, A., Allen, M. D., Jones, J. L., Gribben, J. G., Jurkowski, T. P., & Ficz, G. (2017) · Nature Communications · doi:10.1038/s41467-017-01078-2 · Cited by 113
Leidal, A. M., Cyr, D. P., Hill, R. J., Lee, P. W. K., & McCormick, C. (2012) · Cell Host & Microbe · doi:10.1016/j.chom.2012.01.005 · Cited by 113
“This response is autophagy-dependent; disruption of autophagy with shRNAs targetingATG5 or ATG7 effectively suppressed IL6 and IL8 release (Figures 5C and 5D).”
BackgroundInfluentialThe emerging role of senescent cells in tissue homeostasis and pathophysiology
Tominaga, K. (2015) · Pathobiology of Aging & Age-related Diseases · doi:10.3402/pba.v5.27743 · Cited by 113
“Tumor promotion Although cellular senescence suppresses malignant transformation, secreted factors by SASP such as inflammatory cytokines (IL-1, IL-6, IL-8, MCP2, and others), proteases (MMPs and others), and growth factors (VEGF and others) (60,72) may facilitate the progression of surrounding tumor cells and acceler…”
BackgroundInfluentialAge-Induced Changes in White, Brite, and Brown Adipose Depots: A Mini-Review
Schosserer, M., Grillari, J., Wolfrum, C., & Scheideler, M. (2018) · Gerontology · doi:10.1159/000485183 · Cited by 113
Cellular Senescence - its role in cancer and the response to ionizing radiation
Sabin, R. J., & Anderson, R. M. (2011) · Genome Integrity · doi:10.1186/2041-9414-2-7 · Cited by 113
NF-κB in Cellular Senescence and Cancer Treatment
Hua, J., & Lee, S. (2014) · Molecules and Cells · doi:10.14348/molcells.2014.2353 · Cited by 130
“…publications postulated that senescenceassociated and predominantly NF-κB-driven cytokines, collectively termed “senescence-associated secretory phenotype (SASP)”, may reinforce the senescent cell-cycle arrest (Acosta et al., 2008; Coppe et al., 2008; Kuilmann et al., 2008; Rovillain et al., 2011).”
BackgroundLewinska, A., Adamczyk-Grochala, J., Bloniarz, D., Olszowka, J., Kulpa-Greszta, M., Litwinienko, G., Tomaszewska, A., Wnuk, M., & Pazik, R. (2020) · Redox Biology · doi:10.1016/j.redox.2019.101337 · Cited by 112
Senescent Cells and Their Secretory Phenotype as Targets for Cancer Therapy
Velarde, M. C., Demaria, M., & Campisi, J. (2013) · Interdisciplinary Topics in Gerontology and Geriatrics · doi:10.1159/000343572 · Cited by 112
“Cellular senescence entails a robust increase in the expression and secretion of numerous cytokines, chemokines, growth factors and proteases, which are collectively referred to as the senescence-associated secretory phenotype (SASP) or senescence messaging secretome (SMS) [30, 31].”
BackgroundSelf-citationVitiligo: A Possible Model of Degenerative Diseases
Bellei, B., Pitisci, A., Ottaviani, M., Ludovici, M., Cota, C., Luzi, F., Dell’Anna, M. L., & Picardo, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059782 · Cited by 112
Cellular senescence in the lung across the age spectrum
Parikh, P., Wicher, S., Khandalavala, K., Pabelick, C. M., Britt, R. D., & Prakash, Y. S. (2019) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00424.2018 · Cited by 112
“(44) noted the production of a variety of factors, including IL-1, IL-6, IL-8, MCP-2, MIP-3 , GRO, and IGFBPs with differential expression depending on the cell type affected.”
BackgroundNeilsen, P. M., Noll, J. E., Suetani, R. J., Schulz, R. B., Al-Ejeh, F., Evdokiou, A., Lane, D. P., & Callen, D. F. (2011) · Oncotarget · doi:10.18632/oncotarget.382 · Cited by 112
“Such observations are reminiscent of the hyper-secretory phenotype released from senescent cells referred to as the senescence-associated secretory phenotype (SASP) [35].”
BackgroundInfluentialSenescent Cells: A Therapeutic Target in Cardiovascular Diseases
Suda, M., Paul, K. H., Minamino, T., Miller, J. D., Lerman, A., Ellison-Hughes, G. M., Tchkonia, T., & Kirkland, J. L. (2023) · Cells · doi:10.3390/cells12091296 · Cited by 112
Age-associated alterations in immune function and inflammation
Lewis, E. D., Wu, D., & Meydani, S. N. (2022) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2022.110576 · Cited by 111
Matsudaira, T., Nakano, S., Konishi, Y., Kawamoto, S., Uemura, K., Kondo, T., Sakurai, K., Ozawa, T., Hikida, T., Komine, O., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-05027-2 · Cited by 98
“In addition to irreversible cell-cycle arrest, mainly coordinated by p16 INK4a and p21 Waf1/Cip1 , senescent cells exhibit a secretory phenotype that releases various in fl ammatory cytokines, chemo-kines and growth factors into their extracellular fl uid 15 – 18 .”
Telomeres, Telomerase and Ageing
Saretzki, G. (2018) · Subcellular Biochemistry · doi:10.1007/978-981-13-2835-0_9 · Cited by 93
Lei, X., He, N., Zhu, L., Zhou, M., Zhang, K., Wang, C., Huang, H., Chen, S., Li, Y., Liu, Q., et al. (2021) · Antioxidants & Redox Signaling · doi:10.1089/ars.2019.7965 · Cited by 111
“Ionizing radiation generates high levels of reactive oxygen species and induces DNA damage (13).”
A Proteomic Atlas of Senescence-Associated Secretomes for Aging Biomarker Development
(2019) · doi:10.1101/604306 · Cited by 110
Self-citationEmpowering Adult Stem Cells for Myocardial Regeneration
Mohsin, S., Siddiqi, S., Collins, B. L., & Sussman, M. A. (2011) · Circulation Research · doi:10.1161/circresaha.111.243071 · Cited by 113
Sasaki, M., Miyakoshi, M., Sato, Y., & Nakanuma, Y. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.03.008 · Cited by 115
Hassona, Y., Cirillo, N., Lim, K. P., Herman, A., Mellone, M., Thomas, G. J., Pitiyage, G. N., Parkinson, E. K., & Prime, S. S. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt035 · Cited by 110
“(20) showed that the ability of both fibroblasts and epithelial cells to generate a senescent-associated secretory phenotype and induce EMT was enhanced by the presence of both HRAS and TP53 mutations.”
BackgroundInfluentialChanges in the Transcriptome of Human Astrocytes Accompanying Oxidative Stress-Induced Senescence
Crowe, E. P., Tuzer, F., Gregory, B. D., Donahue, G., Gosai, S. J., Cohen, J., Leung, Y. Y., Yetkin, E., Nativio, R., Wang, L.-S., et al. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00208 · Cited by 110
“…and at sites of aging-related pathology (Price et al., 2002; Krishnamurthy et al., 2004; Herbig et al., 2006; Bhat et al., 2012; Jurk et al., 2012, 2014; Zhu et al., 2014), undergo widespread changes in gene expression, and demonstrate a pro-inflammatory secretion pattern (Coppé et al., 2008).”
BackgroundExpansion and Cell-Cycle Arrest: Common Denominators of Cellular Senescence
Ogrodnik, M., Salmonowicz, H., Jurk, D., & Passos, J. F. (2019) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2019.06.011 · Cited by 104
Treiber, N., Maity, P., Singh, K., Kohn, M., Keist, A. F., Ferchiu, F., Sante, L., Frese, S., Bloch, W., Kreppel, F., et al. (2011) · Aging Cell · doi:10.1111/j.1474-9726.2010.00658.x · Cited by 109
“, 2010) and cytokines (Coppe et al., 2008) have been identified to contribute to skin aging, sarcopenia and osteoporosis in humans and rodents (Zofkova, 2003; Raisz, 2005; Ralston & de Crombrugghe, 2006; Hiona & Leeuwenburgh, 2008; Marzetti et al.”
BackgroundInfluentialEpithelial-mesenchymal transition and senescence: two cancer-related processes are crossing paths
Smit, M. A., & Peeper, D. S. (2010) · Aging · doi:10.18632/aging.100209 · Cited by 108
“It has recently been shown that OIS is accompanied by the induction of several interleukins, revealing that senescence is commonly associated with a robust inflammatory response [31, 71, 72, 73].”
BackgroundCellular senescence: a double-edged sword in cancer therapy
Xiao, S., Qin, D., Hou, X., Tian, L., Yu, Y., Zhang, R., Lyu, H., Guo, D. S., Chen, X., Zhou, C., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1189015 · Cited by 143
Reshaping of the tumor microenvironment by cellular senescence: An opportunity for senotherapies
D’Ambrosio, M., & Gil, J. (2023) · Developmental Cell · doi:10.1016/j.devcel.2023.05.010 · Cited by 119
MicroRegulators come of age in senescence
Gorospe, M., & Abdelmohsen, K. (2011) · Trends in Genetics · doi:10.1016/j.tig.2011.03.005 · Cited by 108
“When cells reach senescence, they secrete numerous proteins, including many cytokines and chemokines [23] with broad implications in oncogenesis and other pathologies.”
BackgroundInfluentialTransmitting senescence to the cell neighbourhood
Hoare, M., & Narita, M. (2013) · Nature Cell Biology · doi:10.1038/ncb2811 · Cited by 108
Honegger, A., Leitz, J., Bulkescher, J., Hoppe‐Seyler, K., & Hoppe‐Seyler, F. (2013) · International Journal of Cancer · doi:10.1002/ijc.28164 · Cited by 108
“”(59) SASP induction has also been demonstrated for epithelial cancer cells undergoing senescence in response to irradiation.(59) It is believed that the SASP plays an important role in the intercellular communication of senescent cells with their environment, for example, by inducing their clearance via the immune sy…”
BackgroundInflammatory Mediators in Oral Cancer: Pathogenic Mechanisms and Diagnostic Potential
Niklander, S. E. (2021) · Frontiers in Oral Health · doi:10.3389/froh.2021.642238 · Cited by 132
“IL-6 and IL-8 Both IL-6 and IL-8 are considered “oncogenic cytokines,” as they are able to cause EMT [88], stimulate angiogenesis and tumor growth [89, 90], disrupt cell–cell communication, impede macrophage function, and promote epithelial and endothelial cell migration and invasion [91].”
BackgroundTo clear, or not to clear (senescent cells)? That is the question
Lujambio, A. (2016) · BioEssays · doi:10.1002/bies.201670910 · Cited by 108
Macrophage senescence in health and diseases
Wang, L., Hong, W., Zhu, H., He, Q., Yang, B., Wang, J., & Weng, Q. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.01.008 · Cited by 130
Inflammation, DNA Damage, Helicobacter pylori and Gastric Tumorigenesis
Kalisperati, P., Spanou, E., Pateras, I. S., Korkolopoulou, P. A., Varvarigou, A. A., Karavokyros, I., Gorgoulis, V. G., Vlachoyiannopoulos, P. G., & Sougioultzis, S. (2017) · Frontiers in Genetics · doi:10.3389/fgene.2017.00020 · Cited by 127
“…of various substances by the senescent cell, including inflammatory cytokines (e.g., IL-6, IL-8), proteases and growth factors (Bavik et al., 2006; Coppe et al., 2008; Malaquin et al., 2013) that act as inflammatory stimulators and affect neighboring non-senescent cells, in a paracrine fashion.”
Backgroundvan Riggelen, J., Müller, J., Otto, T., Beuger, V., Yetil, A., Choi, P. S., Kosan, C., Möröy, T., Felsher, D. W., & Eilers, M. (2010) · Genes & Development · doi:10.1101/gad.585710 · Cited by 107
“Senescence can also occur in response to secretion of multiple cytokines, and the enhanced synthesis of IL6 accounts for the oncogene-induced senescence of human primary fibroblasts (Coppe et al. 2008; Kuilman et al. 2008).”
BackgroundEvidences of Early Senescence in Multiple Myeloma Bone Marrow Mesenchymal Stromal Cells
André, T., Meuleman, N., Stamatopoulos, B., De Bruyn, C., Pieters, K., Bron, D., & Lagneaux, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059756 · Cited by 107
Besancenot, R., Chaligné, R., Tonetti, C., Pasquier, F., Marty, C., Lécluse, Y., Vainchenker, W., Constantinescu, S. N., & Giraudier, S. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000476 · Cited by 106
The bright and dark side of extracellular vesicles in the senescence-associated secretory phenotype
Wallis, R., Mizen, H., & Bishop, C. L. (2020) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2020.111263 · Cited by 108
Stromal Senescence By Prolonged CDK4/6 Inhibition Potentiates Tumor Growth
Guan, X., LaPak, K. M., Hennessey, R. C., Yu, C. Y., Shakya, R., Zhang, J., & Burd, C. E. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0319 · Cited by 106
“, IL6, IL8, CXCL-1, VEGF) promote the proliferation of tumor cells in vitro (8, 9, 11).”
BackgroundQuiescence: Good and Bad of Stem Cell Aging
Tümpel, S., & Rudolph, K. L. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2019.05.002 · Cited by 112
Targeting senescence as an anticancer therapy
Bousset, L., & Gil, J. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13312 · Cited by 105
Li, M., Liao, L., & Tian, W. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.573511 · Cited by 128
Skin-Aging Pigmentation: Who Is the Real Enemy?
Kim, J. C., Park, T. J., & Kang, H. Y. (2022) · Cells · doi:10.3390/cells11162541 · Cited by 135
“Although the compositions and quantities of SASPs can differ according to the types of cells and the initial stimuli, the main components of SASPs in senescent fibroblasts and melanocytes consist of interleukin (IL)-6, IL-8, CXC chemokine ligand (CXCL) 2, MMP3, MMP9, and insulin-like growth-factor-binding protein 7 (I…”
BackgroundHow good is the evidence that cellular senescence causes skin ageing?
Low, E., Alimohammadiha, G., Smith, L. A., Costello, L. F., Przyborski, S. A., von Zglinicki, T., & Miwa, S. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101456 · Cited by 106
“For instance, fibroblasts that enter senescence initially predominantly secrete anti-inflammatory chemokines and TGF-β in a pathway driven by Notch-1 (Hoare and Narita, 2017), while later ROS- and p38MAPK-induced activation of NF-kB and C/EBPbeta results in a pro-inflammatory SASP (Acosta et al., 2008; Coppé et al.,…”
BackgroundInfluentialScarless wound healing: From development to senescence
Pratsinis, H., Mavrogonatou, E., & Kletsas, D. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.04.011 · Cited by 103
Role of cellular senescence in inflammation and regeneration
Saito, Y., Yamamoto, S., & Chikenji, T. (2024) · Inflammation and Regeneration · doi:10.1186/s41232-024-00342-5 · Cited by 139
Transposon-triggered innate immune response confers cancer resistance to the blind mole rat
Zhao, Y., Oreskovic, E., Zhang, Q., Lu, Q., Gilman, A., Lin, Y. S., He, J., Zheng, Z., Lu, J. Y., Lee, J., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-01027-8 · Cited by 99
Regulation of senescence and the SASP by the transcription factor C/EBPβ
Salotti, J., & Johnson, P. F. (2019) · Experimental Gerontology · doi:10.1016/j.exger.2019.110752 · Cited by 103
Abdul-Aziz, A. M., Sun, Y., Hellmich, C., Marlein, C. R., Mistry, J., Forde, E., Piddock, R. E., Shafat, M. S., Morfakis, A., Mehta, T., et al. (2019) · Blood · doi:10.1182/blood-2018-04-845420 · Cited by 105
Perez, K., Ciotlos, S., McGirr, J., Limbad, C., Doi, R., Nederveen, J. P., Nilsson, M. I., Winer, D. A., Evans, W., Tarnopolsky, M., et al. (2022) · Aging · doi:10.18632/aging.204435 · Cited by 103
Self-citationThe impact of radiation therapy on the antitumor immunity: Local effects and systemic consequences
Lumniczky, K., & Sáfrány, G. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.08.024 · Cited by 109
Strategies to Prevent or Remediate Cancer and Treatment-Related Aging
Guida, J. L., Agurs-Collins, T., Ahles, T. A., Campisi, J., Dale, W., Demark-Wahnefried, W., Dietrich, J., Fuldner, R., Gallicchio, L., Green, P. A., et al. (2021) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djaa060 · Cited by 105
Self-citationSenescent cells and macrophages: key players for regeneration?
Elder, S. S., & Emmerson, E. (2020) · Open Biology · doi:10.1098/rsob.200309 · Cited by 117
“(a) The key features of a senescent cell, which include an enlarged and irregular/flattened shape [6], DNA segments with chromatin alterations reinforcing senescence (DNA-SCARS) [9] and foci [10], altered gene expression [8] and cell cycle arrest [7], mitochondrial dysfunction and release of reactive oxygen species (R…”
BackgroundPancreatic cancer tumor microenvironment is a major therapeutic barrier and target
Hartupee, C. D., Nagalo, B. M., Chabu, C. Y., Tesfay, M. Z., Coleman‐Barnett, J., West, J. T., & Moaven, O. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1287459 · Cited by 138
Targeting senescent cells for a healthier longevity: the roadmap for an era of global aging
Sun, Y., Li, Q., & Kirkland, J. L. (2022) · Life Medicine · doi:10.1093/lifemedi/lnac030 · Cited by 105
Self-citationEvidence and perspectives of cell senescence in neurodegenerative diseases
Si, Z., Sun, L., & Wang, X. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111327 · Cited by 105
Molecular Mechanisms of Intervertebral Disc Degeneration
Rider, S. M., Mizuno, S., & Kang, J. D. (2018) · Spine Surgery and Related Research · doi:10.22603/ssrr.2017-0095 · Cited by 112
Wang, Z., Deng, Z., Dahmane, N., Tsai, K., Wang, P., Williams, D., Kossenkov, A. V., Showe, L. C., Zhang, R., Huang, Q., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1505962112 · Cited by 111
“Cells with short telomeres produce a distinct pattern of cytokines that has been referred to as a telomere-associated secretory phenotype (TASP), which is distinct from SASP (5, 44).”
BackgroundVolonte, D., Zou, H., Bartholomew, J. N., Liu, Z., Morel, P. A., & Galbiati, F. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.598268 · Cited by 104
Wiggins, K. A., Parry, A. J., Cassidy, L. D., Humphry, M., Webster, S. J., Goodall, J. C., Narita, M., & Clarke, M. C. H. (2019) · Aging Cell · doi:10.1111/acel.12946 · Cited by 104
Iakovou, E., & Kourti, M. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.827900 · Cited by 129
“Nuclear factor-kappa B (NF-κB) also plays an important role in the occurrence of the SASP phenotype (Coppé et al., 2008; Birch and Passos, 2017; Song et al., 2020).”
BackgroundRuzankina, Y., Schoppy, D. W., Asare, A., Clark, C. E., Vonderheide, R. H., & Brown, E. J. (2009) · Nature Genetics · doi:10.1038/ng.441 · Cited by 97
“Occupancy of tissues by genetically unstable cells might delay tissue renewal either by obstructing competent progenitors from interacting with key environmental cues or by causing the generation of secreted factor”
Yang, H., Chen, C., Chen, H., Duan, X., Li, J., Zhou, Y., Zeng, W., & Yang, L. (2020) · Aging · doi:10.18632/aging.103177 · Cited by 104
Autophagy and senescence in fibrosing cholangiopathies
Nakanuma, Y., Sasaki, M., & Harada, K. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.11.027 · Cited by 103
Blackburn, E. H. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0195 · Cited by 103
“may promote cancer progression in neighboring cells (41).”
BackgroundPitiyage, G. N., Slijepcevic, P., Gabrani, A., Chianea, Y. G., Lim, K. P., Prime, S. S., Tilakaratne, W. M., Fortune, F., & Parkinson, E. K. (2011) · The Journal of Pathology · doi:10.1002/path.2839 · Cited by 101
Biomarkers of Physical Frailty and Sarcopenia: Coming up to the Place?
Picca, A., Calvani, R., Cesari, M., Landi, F., Bernabei, R., Coelho-Júnior, H. J., & Marzetti, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165635 · Cited by 100
PRMT5 as a druggable target for glioblastoma therapy
Banasavadi‐Siddegowda, Y., Welker, A. M., An, M. J., Yang, X. T., Zhou, W., Shi, G., Imitola, J., Li, C., Hsu, S. H., Wang, J., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox206 · Cited by 112
Chromatin basis of the senescence-associated secretory phenotype
Hao, X., Wang, C., & Zhang, R. (2022) · Trends in Cell Biology · doi:10.1016/j.tcb.2021.12.003 · Cited by 94
Tato-Costa, J., Casimiro, S., Pacheco, T. R., Pires, R., Fernandes, A., Alho, I., Pereira, P., Costa, P., Castelo, H. B., Ferreira, J. A., et al. (2015) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2015.09.003 · Cited by 126
“This finding supports a role for the microenvironment in rectal cancer behavior.26 Also, the treatment of patients with cancer using DNA-damaging agents, in both neoadjuvant and curative settings, was shown to induce epithelial cancer cells into accelerated forms of senescence.14 Senescent cells derived from either no…”
BackgroundSenescent Fibroblasts Enhance Early Skin Carcinogenic Events via a Paracrine MMP-PAR-1 Axis
Malaquin, N., Vercamer, C., Bouali, F., Martien, S., Deruy, E., Wernert, N., Chwastyniak, M., Pinet, F., Abbadie, C., & Pourtier, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063607 · Cited by 101
NOTCH-mediated non-cell autonomous regulation of chromatin structure during senescence
Parry, A. J., Hoare, M., Bihary, D., Hänsel-Hertsch, R., Smith, S., Tomimatsu, K., Mannion, E., Smith, A., D’Santos, P., Russell, I. A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04283-9 · Cited by 102
Constitutive HER2 Signaling Promotes Breast Cancer Metastasis through Cellular Senescence
Angelini, P. D., Fluck, M. F. Z., Pedersen, K., Parra-Palau, J. L., Guiu, M., Bernadó Morales, C., Vicario, R., Luque-García, A., Navalpotro, N. P., Giralt, J., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2301 · Cited by 100
“Accordingly, in vitro, the secretome of senescent cells increases cell proliferation (23, 24), angiogenesis, and invasion (21).”
BackgroundThe role of myeloid-derived suppressor cells (MDSC) in the inflammaging process
Salminen, A., Kaarniranta, K., & Kauppinen, A. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.09.001 · Cited by 107
Palangat, M., Anastasakis, D. G., Fei, D. L., Lindblad, K. E., Bradley, R., Hourigan, C. S., Hafner, M., & Larson, D. R. (2019) · Genes & Development · doi:10.1101/gad.319590.118 · Cited by 102
“These results bear a resemblance to the phenomenon of oncogene-induced senescence, where nonproliferating cells contribute to oncogenesis through secretion of factors into the surrounding tissue (Krtolica et al. 2001; Bavik et al. 2006; Liu and Hornsby 2007; Coppé et al. 2008).”
Cellular senescence and tumor promotion: Is aging the key?
Loaiza, N., & Demaria, M. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.01.007 · Cited by 101
Binet, R., Ythier, D., Robles, A. I., Collado, M., Larrieu, D., Fonti, C., Brambilla, E., Brambilla, C., Serrano, M., Harris, C. C., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1016 · Cited by 101
Crespo‐Garcia, S., Fournier, F., Diaz-Marin, R., Klier, S. M., Ragusa, D., Masaki, L., Cagnone, G., Blot, G., Hafiane, I., Dejda, A., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02802-4 · Cited by 121
“This state is termed the senescence-associated secretory phenotype (SASP), and modifies the proximal cellular environment and extracellular matrix 17 (reviewed in ref.”
Hypoxia and Senescence: The Impact of Oxygenation on Tumor Suppression
Welford, S. M., & Giaccia, A. J. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-11-0065 · Cited by 108
Conserved senescence associated genes and pathways in primary human fibroblasts detected by RNA-seq
Marthandan, S., Baumgart, M., Priebe, S., Groth, M., Schaer, J., Kaether, C., Guthke, R., Cellerino, A., Platzer, M., Diekmann, S., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0154531 · Cited by 91
“We selected a set of genes which, in these two cell strains, were most differentially expressed with age (CTSK, DKK3, TMEM47, CCNB1, CCNA2, C3,Wnt16, IGFBP2 and CCND1) and p21, expected to be significantly up-regulated with age [31, 82, 83].”
BackgroundResultKletsas, D. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1132 · Cited by 100
Molecular pathways of senescence regulate placental structure and function
Gal, H., Lysenko, M., Stroganov, S., Vadai, E., Youssef, S. A., Tzadikevitch‐Geffen, K., Rotkopf, R., Biron‐Shental, T., de Bruin, A., Neeman, M., et al. (2019) · The EMBO Journal · doi:10.15252/embj.2018100849 · Cited by 99
“The SASP, composed of pro-inflammatory cytokines, chemokines, growth factors, and proteases, can modulate the senescent cell’s microenvironment and promote its interaction with the immune system (Coppe et al , 2008; Lujambio et al , 2013; Sagiv & Krizhanovsky, 2013; Sagiv et al , 2016).”
Cellular senescence and the skeleton: pathophysiology and therapeutic implications
Khosla, S., Farr, J. N., & Monroe, D. G. (2022) · Journal of Clinical Investigation · doi:10.1172/jci154888 · Cited by 100
Principles of the Molecular and Cellular Mechanisms of Aging
da Silva, P. F. L., & Schumacher, B. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.11.018 · Cited by 100
Stem cell depletion in Hutchinson–Gilford progeria syndrome
Rosengardten, Y., McKenna, T., Grochová, D., & Eriksson, M. (2011) · Aging Cell · doi:10.1111/j.1474-9726.2011.00743.x · Cited by 99
“Expression of SASP factors is dependent on a function of the transcription factor NF-kB, and it has been shown that cells lacking lamin A ⁄ C proteins fail to activate efficient transcription by NF-kB (Lammerding et al., 2004).”
BackgroundMethodInfluentialReproductive Ageing: Inflammation, immune cells, and cellular senescence in the aging ovary
Isola, J. V. V., Hense, J. D., Osorio, C. A. P., Biswas, S., Alberola‐Ila, J., Ocañas, S. R., Schneider, A., & Stout, M. B. (2024) · Reproduction · doi:10.1530/rep-23-0499 · Cited by 134
Morphological and Functional Characteristic of Senescent Cancer Cells
Sikora, E., Mosieniak, G., & Alicja Sliwinska, M. (2016) · Current Drug Targets · doi:10.2174/1389450116666151019094724 · Cited by 99
Metadata
- Authors
- Coppé, J.-P., Patil, C. K., Rodier, F., Sun, Y., Muñoz, D. P., Goldstein, J., Nelson, P. S., Desprez, P.-Y., & Campisi, J.
- Affiliations
- Lawrence Berkeley National Laboratory (US)
- Fred Hutch Cancer Center (US)
- Buck Institute for Research on Aging (US)
- Corresponding author
- Campisi, Judith
- Venue
- PLoS Biology
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-12-02
- Volume
- 6
- Issue
- 12
- Pages
- e301
- ISSN
- 1544-9173 (ISSN-L)
- 1545-7885
- PMC
- PMC2592359
- OpenAlex
- W239602587
- Cited by
- 302
- References
- 81
- Citations by year
- 2025: 16 · 2024: 29 · 2023: 30 · 2022: 38 · 2021: 49 · 2020: 26 · 2019: 15 · 2018: 12 · 2017: 16 · 2016: 16 · 2015: 11 · 2014: 8 · 2013: 4 · 2012: 9
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Biology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of North Texas Digital Library (University of North Texas) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Lawrence Berkeley National Laboratory
- Funders
- Larry L. Hillblom Foundation
- University of Washington
- National Institutes of Health (AG09909, AG017242, CA126540, AG000266)
- National Institute on Aging (R56AG009909, AG017242, AG-09909, R37AG009909, AG000266, P01AG017242, T32AG000266)
- National Cancer Institute (CA126540, CA 97186, U54CA126540, P50CA097186)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- senescence-associated secretory phenotype, cellular senescence, genotoxic stress, oncogenic Ras, p53 tumor suppressor, paracrine signaling, interleukin-6, interleukin-8, epithelial-mesenchymal transition, tumor invasion, prostate cancer chemotherapy, tissue microenvironment, age-related cancer
- MeSH terms
- Adult, Aging, Antineoplastic Agents, Cells, Cultured, Epithelial Cells, Fibroblasts, Humans, Infant, Newborn, Male, Neoplasm Invasiveness, Neoplasms, Phenotype, Prostatic Neoplasms, Genes, ras, Interleukin-6, Tumor Suppressor Protein p53, Interleukin-8, Cellular Senescence, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.